【中泰证券】医药生物行业报告简版：创新药价值分析：First-in-Class、Best-in-Class哪个更重要？市场推广投入对市场份额影响有多大？.pdf

the-value-of-chinas-emerging-middle-class

创新药周报：TGCT进展不断，和誉有望best-in-class

聚焦抗体药物创新，多个First in class产品未来可期

医药生物行业周报：Dato-DXd有望成为全球首个治疗肺癌的 TROP2 ADC，国产SKB 264有潜力成为Best in class

ASC41公布2期期中数据，具备同靶点best-in-class潜质

The best-in-class costs management in 2Q24

Best-in-Class Professional Services Management

Trends in infrastructure: An evolving asset class

创新药周报：TGCT进展不断，和誉有望top-in-class